{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Advances in Lung Cancer Treatment
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the indications for and therapeutic actions of the newer pharmacologic treatments for lung cancer.
- Select the adverse effects of the newer pharmacologic treatments for lung cancer.
- Choose the appropriate home healthcare considerations for patients receiving pharmacologic treatments for lung cancer.
Learning Outcomes
Seventy-five percent of participants will demonstrate knowledge of and competency in clinical reasoning regarding recent advances in lung cancer treatment that have achieved long-term remission and survival by achieving a minimum score of 70% on the outcomes-based posttest.Disclosures
The author and planners have no relevant financial relationships with any ineligible organizations regarding this activity.
Price:
$21.95
Credits:
- ANCC 2.0 CH
- DC - BON 2.0 CH
- FL - BON 2.0 CH
- GA - BON 2.0 CH
- NM - BON 2.0 CH
- SC - BON 2.0 CH
- WV - BOERN 2.0 CH
Lippincott Professional Development is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Professional Development is also an approved provider of continuing nursing education by the District of Columbia Board of Nursing, Florida Board of Nursing, Georgia Board of Nursing, New Mexico Board of Nursing, South Carolina Board of Nursing, and West Virginia Board of Examiners for Registered Professional Nurses, #50-1223.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: HHCN1122
Published: Nov/Dec 2022
Expires: 12/5/2025
Sources:
Home Healthcare Now
Required Passing Score: 8/10 (80%)